Onl Therapeutics Closes First Tranche Of $15 Million Series C Financing To Advance Lead Compound Into Phase 2 Clinical Trial
Onl Therapeutics Closes First Tranche Of $15 Million Series C Financing To Advance Lead Compound Into Phase 2 Clinical Trial
03/08/23, 12:15 PM
Location
ann arborMoney raised
$15 million
Industry
biopharma
health care
Round Type
series c
ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced it has closed on the first tranche of a $15 million Series C Preferred Stock financing round. Proceeds from the financing will primarily support the advancement of ONL1204 Ophthalmic Solution into a Phase 2 clinical trial in patients with macula-off rhegmatogenous retinal detachment (RRD).
Company Info
Location
524 s. main st
ann arbor, michigan, united states
Additional Info
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision.